Common Stock, par value $0.001 per share
- Symbol
- TNDM
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Tandem Diabetes Care, Inc.
TNDMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition . On February 19, 2026, we issued a press release reporting our financial results for the quarter and year ended December 31, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.…
Press release in this filing
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance →Company context
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is headquartered in San Diego, California. For more information, visit tandemdiabetes.com.
Current securities
Historical securities (1)
Registered securities in this filing
Tandem Diabetes Care, Inc. · 8-K · Filed 2026-02-19
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition
.
On February 19, 2026, we issued a press release reporting our financial results for the quarter and year ended December 31, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance San Diego, February 19, 2026 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial and Strategic Highlights • Achieved record quarterly sales: ◦ Worldwide sales of $290.4 million ◦ United States sales of $210.5 million ◦ Worldwide pump shipments of 38,000 ◦ United States pump shipments of 27,000 • Delivered meaningful operational improvement: ◦ Record quarterly gross margin of 58% ◦ Operating income of $8.3 million, or 3% of sales ◦ Net loss of $0.6 million with positive adjusted EBITDA(1) of 11% of sales ◦ Positive cash flow from operating activities of $9.8 million and positive free cash flow(1) of $3.1 million • Delivered key portfolio enhancements: ◦ Began global co…
Open exhibit ↗